Alterity Therapeutics Limited

ASX (AUD): Alterity Therapeutics Limited (ATH)

Last Price

0.003

Today's Change

0.00 (0.00%)

Day's Change

0.003 - 0.003

Trading Volume

3,864,555

Profile
ATH

Exchange:  Australian Securities Exchange Australian Securities Exchange

Currency:  AUD AUD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Dr. David A. Stamler M.D. Dr. David A. Stamler M.D.

Full Time Employees:  10 10

IPO Date:  2000-03-28 2000-03-28

CIK: 

ISIN:  AU0000043945 AU0000043945

CUSIP:  Q02676106 Q02676106

Beta:  0.68 0.68

Last Dividend:  0.00 0.00

Dcf Diff:  0.00 0.00

Dcf:  0.00 0.00

Description

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Address

460 Bourke Street,
Melbourne, VIC 3000, AU

61 3 9349 4906

http://alteritytherapeutics.com

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment